CN111544470A - 一种治疗心力衰竭的中药组合物 - Google Patents
一种治疗心力衰竭的中药组合物 Download PDFInfo
- Publication number
- CN111544470A CN111544470A CN202010464299.1A CN202010464299A CN111544470A CN 111544470 A CN111544470 A CN 111544470A CN 202010464299 A CN202010464299 A CN 202010464299A CN 111544470 A CN111544470 A CN 111544470A
- Authority
- CN
- China
- Prior art keywords
- parts
- heart failure
- traditional chinese
- chinese medicine
- treating heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 7
- 240000005748 Achyranthes aspera Species 0.000 claims abstract description 6
- 235000005517 Achyranthes aspera Nutrition 0.000 claims abstract description 6
- 241000893536 Epimedium Species 0.000 claims abstract description 6
- 241000028204 Vincetoxicum atratum Species 0.000 claims abstract description 6
- 235000018905 epimedium Nutrition 0.000 claims abstract description 6
- 241001116477 Adenophora triphylla Species 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 210000000582 semen Anatomy 0.000 claims abstract description 4
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 3
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 3
- 244000234609 Portulaca oleracea Species 0.000 claims abstract 3
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 5
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 240000007371 Cuscuta campestris Species 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 210000002216 heart Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- 241000219304 Portulacaceae Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- -1 resveratrol glucoside Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 229930182836 (R)-noradrenaline Natural products 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗心力衰竭中药组合物，是由下列重量份的原料药组成：白薇、淫羊藿4.5～9份；菟丝子、虎杖、马齿苋、南沙参9～18份；土牛膝15～30份。本发明具有治疗效果显著、治疗周期短、无毒副作用等特点。
Description
技术领域
本发明属于中药技术领域，尤其是涉及一种治疗心力衰竭 的中药组合物。
背景技术
心力衰竭是各种心脏疾病导致心功能不全的一种复杂临床综合症，是一种心室泵血能力下降,心排血量降低，不能满足机体代谢需要的疾病。
心衰患者容易复发，西药治疗效果差，某些服用地高辛容易中毒、服用ACEI容易出现咳嗽、使用利尿剂容易出现低钾低钠等副反应严重的患者，或具有禁忌、慎用西药的患者，如心率缓慢等。
发明内容
本发明的目的在于改进已有技术的不足而提供一种心力衰竭的中药组合物，具有治疗效果显著、治疗周期短、无毒副作用等特点。
“心衰”一词，却最早出现于宋代《圣济总录・心脏门》：“心衰则健忘，不足则胸腹胁下与腰背引痛，惊悸，恍惚，少颜色，舌本强”。与“心衰”有关的描述，则最早见于《内经》：“心胀者，烦心短气，卧不安”，“心痹者，脉不通，烦则心下鼓，上气而喘”。心力衰竭在临床上多见于“心悸”“怔忡”“喘证”“水肿”“痰饮”“心水”等病证中。
中医认为，病之初期，痰、淤、水阴邪内盛，阳气未虚；病之中期，阳虚与痰浊水淤并见；病之晚期，阳损及阴，阴阳双虚。
治疗心力衰竭，应温补心肺肾阴，振奋阳气，同时补肺脾之气，滋养营阴以助阳，达到机体整体阴阳气血的平衡。
基于上述理论，本发明的技术方案是：一种内服用于治心力衰竭的中药，由下列重量份的原料药组成：白薇、淫羊藿4.5～9份；菟丝子、虎杖、马齿苋、南沙参9～18份；土牛膝15～30份；
在一个优选的实施方案中，所述治疗心力衰竭的中药组合物由下列重量份的原料药组成：白薇、淫羊藿9份；菟丝子、虎杖、马齿苋、南沙参18份；土牛膝30份；
其中， 虎杖:微苦，微寒。归肝、胆、肺经。活血散瘀；祛风通络；清热利湿；解毒定痛，止咳化痰。
虎杖有明显降压和减慢心率作用。虎杖明显抑制血小板聚集作用，能改善微循环和兴奋肌心细胞，对心脏有明显的正性肌力作用，对抗心力衰竭。所含白藜芦醇葡萄糖甙(PD)对缺糖、缺氧及损伤的心肌细胞有保护作用。
白薇：苦、咸，寒。归胃、肝、肾经。清热益阴，利尿通淋，解毒疗疮。白薇能直接加强心肌收缩，心率变慢，可治疗充血性心力衰竭。
淫羊藿：辛、甘，温。归肝、肾经。补肾阳，强筋骨，祛风湿。淫羊藿显著增加心的冠脉流量均可使其冠脉流量平均增加126.6%， 并能显著减少冠脉阻力，明显增加心肌张力，明显增强心肌收缩力，可使心力衰竭患者心肌张力恢复。淫羊藿有明显降血压，对急性心肌缺血有保护作用，减慢心率。
土牛膝：性味微苦，凉。活血祛瘀；泻火解毒；利尿通淋。土牛膝能使心的收缩力明显加强。当心脏处于衰竭状态时，可使其张力增强。
菟丝子：甘，温。归肝、肾、脾经。补肾益精；养肝明目；固精缩尿，安胎，明目，止泻。菟丝子提取物能产生明显的强心作用。
南沙参：甘，微寒。归肺、胃经。养阴清肺，化痰，益气。
南沙参有明显强心作用，使心的振幅比原来增大50％以上。
马齿苋：味酸，寒。清热利湿，活血消肿，凉血解毒。马齿苋含有丰富的L-去甲肾上腺素可以激发血管B—受体，使冠脉流量增加，使心肌收缩力和心脏的自动节律增强。马齿苋含丰富的ω-3脂肪酸，能抑制胆固醇和甘油三酸酯的生成，对降低心血管病的发生有很好的作用。
本发明是由中国传统的中草药制成，根据中医辨证论治及现代医学的若干原则，以某些成分确定、功效明晰的天然提取物的有序配伍，组合成了治疗心力衰竭的中药组合物。
本发明具有心力衰竭的功效，能够增强机体免疫功能，有效治疗 等，安全可靠无明显毒副反应，不伤脾胃，便于患者长期坚持服用，标本兼治，不易复发。
本发明的中药组合物药味数目少，原料易得，工艺简单，成本低，效率高，有利于制药企业进行药品生产、质量控制；产品价格低，易于被患者接受。
本发明的中药组合物治心力衰竭效果显著，临床实验结果显示，用本药方施治，每日一剂，水煎100-150ml，分成两份，早晚各一份服用，一个月为一个疗程，5-6个疗程治愈率为56％，近控及显效率94%，总有效率为100％，治疗组治疗后患者的 等症状均有显著改善。
本发明治疗费用相对低廉，远远低于西医的治疗费用。
本发明还提供了一种由上述治疗心力衰竭 的中药组合物制成的口服制剂，所述口服制 剂包括口服液、片剂、胶囊剂、丸剂等，优选剂型为片剂和胶囊剂，一日一剂，分早晚两次服用。
本发明的中药组合物可以制备成多种剂型。例如，将煎煮后的药液杀菌消毒后装袋，制成口服液；或者将煎煮后的药液进行浓缩，烘干后，加入医学上可接收的辅料，然后制成片剂、胶囊剂、丸剂等。
所述医学上可接收的辅料包括淀粉、糊精、羧甲基纤维素钠、聚乙二醇、磷酸氢钙、海藻酸钠、山梨酸钾等。
以上所述，仅是本发明的较佳实施例而已，并非对本发明作任何形式上的限制，本领域技术人员利用上述揭示的技术内容做出些许简单修改、等同变化或修饰，均落在本发明的保护范围内。
Claims (4)
1.一种治疗心力衰竭的中药组合物，其特征在于，该中药组合物包括：白薇、淫羊藿4.5～9份；菟丝子、虎杖、马齿苋、南沙参9～18份；土牛膝15～30份。
2.根据权利要求1所述的一种治疗心力衰竭的中药，其特征是由下列重量份的原料药组成：白薇、淫羊藿9份；菟丝子、虎杖、马齿苋、南沙参18份；土牛膝30份。
3.一种治疗心力衰竭的的口服制剂，其特征是由权利要求1或2中任一项所述的中药组合物制成。
4.根据权利要求3所述的一种治疗心力衰竭的口服制剂，其特征是包括口服液、片剂、胶囊剂、丸剂，优选胶囊剂和片剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010464299.1A CN111544470A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗心力衰竭的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010464299.1A CN111544470A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗心力衰竭的中药组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111544470A true CN111544470A (zh) | 2020-08-18 |
Family
ID=72006742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010464299.1A Pending CN111544470A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗心力衰竭的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111544470A (zh) |
-
2020
- 2020-05-28 CN CN202010464299.1A patent/CN111544470A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1344547A (zh) | 多效健胃丸 | |
| CN101306138B (zh) | 一种治疗胸痹心痛的中药制剂及其制备方法 | |
| CN105012735B (zh) | 一种补气血抗癌中药组合物 | |
| CN1173726C (zh) | 一种治疗恶性肿瘤病的药物及其制备方法 | |
| CN111529579A (zh) | 一种醒酒、治疗酒精肝的中药组合物 | |
| CN102210839A (zh) | 一种治疗冠心病的中药胶囊 | |
| CN111544470A (zh) | 一种治疗心力衰竭的中药组合物 | |
| CN113181258A (zh) | 一种治疗月经不调、痛经、闭经的中药组合物 | |
| CN100386111C (zh) | 肝胆胃复康合剂及其制备方法 | |
| CN113144076A (zh) | 一种治疗心肌炎的中药组合物 | |
| CN105396017A (zh) | 一种治疗脂肪肝的中药制剂及其制备方法 | |
| CN111529576A (zh) | 一种治疗脂肪肝的中药组合物 | |
| CN104524461A (zh) | 一种治疗心肌炎的药物组合物及其应用 | |
| CN109078157A (zh) | 一种抗肿瘤药物及其制备方法 | |
| CN104352954A (zh) | 一种抗幽门螺旋杆菌的复方中药配方 | |
| CN100571739C (zh) | 治疗心血管疾病的复方中药及其制备方法 | |
| CN107854685A (zh) | 一种具有抗肿瘤作用的中药组合物及其制备方法和用途 | |
| CN107669910A (zh) | 治疗动脉粥样硬化的药物组合物 | |
| CN111714601A (zh) | 一种治疗真菌感染的中药组合物 | |
| CN116019878A (zh) | 一种治疗糖尿病的中药有效部位组合物 | |
| CN111658697A (zh) | 一种治疗慢性肠炎的中药组合物 | |
| CN105853851A (zh) | 治疗心力衰竭的温阳益气散 | |
| CN116115705A (zh) | 一种治疗心肌梗塞的中药组合物 | |
| CN103800595A (zh) | 一种治疗玻璃体猪囊虫病的中药 | |
| CN108295184A (zh) | 用于治疗胃溃疡的中草药方剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200818 |